Fundraising FoxLeVert Ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Lindy Biosciences develops biotherapeutic drug delivery technology using a proprietary Microglassification platform to reformulate antibody therapeutics into forms patients can self-administer at home instead of via intravenous infusion.
BiotechDeep TechMedical DevicesResearch Triangle Park, US
Deborah Bitterfield(Executive Officer, Director, Promoter)inKaren LeVert(Executive Officer, Director)Sreekar Gadde(Director)in
Board seatKaren LeVert· per SEC Form D · $2.5M raise · filed Mar 2024
Co-investorsArieal Southeast Angel PartnersGood Growth Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.